RVP Stock Gains Post Q2 Earnings Despite Fall in Sales & Unit Volumes

Retractable reported second-quarter 2026 net sales of $7.2 million, down 31.1% from $10.4 million a year earlier. Net income applicable to common shareholders was $2.8 million against a loss of $145,082 in the prior-year quarter, while earnings per share were $0.09 against a loss per share of $0.00.

RVP operates in a single reportable segment comprising safety medical syringes and other safety medical devices. By product, syringe sales increased 5.4% to $6.3 million, while blood collection product sales declined 2.3% to $295,940. EasyPoint needle sales plunged 84.6% to $646,418, and other product sales fell 59.7% to $7,713.

RVP’s Other Key Business Metrics

Domestic revenues declined 30.8% year over year, while domestic unit sales fell 35.1%. Domestic sales represented 81.6% of quarterly revenues compared with 81.3% a year ago. International revenues decreased 32.2%, mainly because of lower EasyPoint needle sales. Overall unit sales declined 36.4%.

Cost of manufactured product fell 34.7% and royalty expense decreased 20.8%. Despite the sharp revenue contraction, gross profit improved to $190,852 from a gross loss of $107,090. The operating loss, however, remained essentially unchanged at $5.1 million.

RVP sourced 53.5% of its second-quarter products from Chinese manufacturers, down from 62% a year earlier.

For the first six months of 2026, cash used in operating activities narrowed to $3.1 million from $5.2 million a year earlier. As of June 30, cash and cash equivalents stood at $2.6 million, while investments in debt and equity securities totaled $37.2 million. Inventories declined to $15.9 million from $17.2 million as of Dec. 31, 2025.

Management Commentary and Factors Influencing Retractable’s Results

Management attributed the weaker quarterly sales and unit volumes primarily to the timing of EasyPoint product orders. The year-over-year comparison was also affected by unusually high flu-season product purchases in the second quarter of 2025. Purchasing in 2026 has followed a more traditional pattern, under which most flu-season sales occur in the third quarter.

Quarterly net income benefited materially from a $6.4 million realized gain on the sale of equity securities. By comparison, the year-ago quarter included $1.9 million of litigation proceeds and a $1.6 million unrealized investment gain.

Second-quarter 2026 tariff expense was approximately $46,000, with RVP attributing lower tariff costs versus prior periods to strategic sourcing and increased domestic production.

Tariff exposure remains significant. As of Aug. 1, 2026, most syringe and needle products imported from China faced a 112.5% tariff rate. Retractable is seeking to mitigate the impact through strategic ordering and greater domestic manufacturing.

RVP’s Outlook

Retractable expects international sales of VanishPoint syringes and EasyPoint needles to increase in the second half of 2026 following certification under the European Union Medical Device Regulation. The company also expects commercial quantities of domestically produced 0.5-milliliter syringes to become available as market demand requires during the second half. However, management cautioned that tariffs could continue to materially affect sourcing, operating results and financial position, while near-term manufacturing costs are expected to remain high as domestic production expands.

Retractable’s Other Developments

In April 2026, Retractable reduced its workforce by approximately 16%. The restructuring is expected to generate about $2.2 million in annual wage and benefit savings, equivalent to 13% of estimated workforce costs, partly offset by approximately $122,000 of one-time separation payments. About 58% of the targeted payroll reduction involved manufacturing or manufacturing-support positions, with the remainder affecting sales and sales-support roles.

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."

Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention. 

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research